October 24, 2025 11:39 ET | Source: PMV Pharmaceuticals, Inc. Data presented today as an oral presentation at 2025 AACR-NCI-EORTC…
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
September 19, 2025 16:18 ET | Source: MBX Biosciences, Inc. CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences,…
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative…